A global study found group differences in an Alzheimer’s blood biomarker. Learn how the findings relate to amyloid, clinical testing and memory concerns.
On October 13, 2026, the Keck School of Medicine of USC reported a global study of Alzheimer’s blood-biomarker measurements in 15,612 cognitively unimpaired adults screened for the AHEAD 3-45 trials. Average levels differed across racial and ethnic groups while the marker’s relationship with brain amyloid was broadly similar across the racial groups studied.
According to USC, the study examined adults aged 55 to 80 screened at 106 research sites across Asia and Australia plus Europe and North America. Participants were cognitively unimpaired, meaning they did not have cognitive impairment at screening.
The researchers studied %p-tau217, a blood measure of the proportion of a protein fragment carrying an Alzheimer’s-related modification. They compared the blood measurements with brain amyloid measured by PET scans.
Two questions guided the comparison: Did average blood-biomarker levels differ between groups? And did the relationship between that blood measure and brain amyloid follow a similar pattern across groups?
Those questions are related, but they are not the same. Comparing average levels describes differences between groups. Comparing the blood measure with PET results examines how closely the marker relates to the brain change that researchers are trying to identify.
USC reported that average %p-tau217 levels tended to be:
At the same time, higher %p-tau217 was consistently associated with higher PET-measured brain amyloid across the racial groups studied. The relationship between the blood marker and brain amyloid was broadly similar across those groups.
The central finding therefore has two parts. Group averages differed, yet the blood marker retained a similar relationship with amyloid across the racial groups examined. Neither part should be dropped when describing the result.
USC also reported that people carrying the APOE ε4 variant tended to have higher %p-tau217 levels than people without it. That pattern largely held across racial and ethnic groups. Corresponding author Doris P. Molina-Henry cautioned that the strength of this relationship can vary across populations.
The AHEAD 3-45 trials are testing lecanemab in people with certain levels of brain amyloid but no Alzheimer’s symptoms. In the screening process described by USC, blood testing helped identify potential participants for further assessment.
Eligible individuals then proceeded to additional assessments, including PET scans. The blood result was therefore part of a research workflow with several stages.
This context matters to the announcement. The study examined a biomarker within trial screening, where researchers were identifying people who might meet specific research criteria. That is a different task from evaluating the cause of someone’s memory concerns in ordinary clinical care.
The immediate value is a clearer basis for interpreting research. The findings bring a large international screening cohort into the discussion about blood biomarkers across racial and ethnic groups.
For clinicians and researchers, the result makes it useful to keep group averages separate from the relationship between a marker and brain amyloid. A difference in the first does not automatically establish a difference in the second. This study provides evidence about both questions within its trial-screening setting.
For someone noticing changes in memory or thinking, the practical step remains a discussion with a clinician. The clinician can assess the symptoms and decide whether biomarker testing would help clarify their cause or affect care.
In a separate BrightFocus discussion, Washington University neurologist Joan Schindler explained that results need clinical context. That includes a person’s symptoms and the specific test used. The laboratory’s reference range also matters.
BrightFocus notes that there is no universal p-tau217 range. A number on a laboratory report should therefore be discussed in relation to the actual test rather than compared with an unrelated result found online.
This is where combining biomarker information with cognitive assessment becomes a useful topic to understand. The practical question is not simply whether a blood marker was measured, but how that information fits the assessment being made.
For researchers, the study also points to a reporting priority: describe average group levels and the marker’s relationship with brain amyloid separately. Presenting only one could leave readers with an incomplete account of the findings.
The study supports a specific research finding. Several broader conclusions would go beyond the evidence reported.
No individual diagnosis or risk estimate follows from these group averages. The report does not provide a method for interpreting a person’s result based on racial or ethnic identity.
Molina-Henry also noted that dementia risk is complex. Contributors beyond the Alzheimer’s-related changes measured by the blood test or PET scan warrant further study.
The useful reading is therefore narrow: these were differences in a blood measure within a trial-screening cohort. They were not a ranking of individual brain health or future dementia risk.
The USC report does not establish that every Alzheimer’s blood test performs equally well across populations. It also does not show whether these findings apply to people with cognitive impairment or to the general population.
The report leaves several details unreported:
Without those details, the findings should not be turned into claims about interchangeable tests or group-specific thresholds. Researchers and clinicians need evidence about the particular test and intended use before making that judgment.
In the BrightFocus discussion, Schindler said clinicians do not usually recommend blood or spinal-fluid biomarker testing for cognitively unimpaired people outside research or clinical trials. That advice also applies to PET biomarker testing in this setting.
BrightFocus further notes that a positive result does not establish that a cognitively unimpaired person will develop Alzheimer’s during their lifetime. The USC study does not establish a home test or a stand-alone diagnosis.
Readers weighing this question can find further context in FitBrainLab’s coverage of biomarker screening when there are no cognitive symptoms. A clinician can address whether testing serves a clear purpose in an individual situation.
The USC report provides no treatment results from AHEAD 3-45. It does not show that any intervention changes an individual’s %p-tau217 level or dementia risk, and it does not change everyday memory-management advice.
USC also describes the Alzheimer’s Plasma Extension Study (APEX). It is following people screened for AHEAD 3-45 who did not meet the trials’ amyloid eligibility criteria. APEX is collecting blood tests and PET scans alongside cognitive measures, but the report provides no APEX results.
These are research questions being followed over time, not established instructions for changing treatment or daily habits.
The study matters because useful biomarker research needs to describe both variation between people and the relationship between a test result and the brain changes it measures. This global cohort contributes evidence on both fronts.
The editorial takeaway is precision rather than urgency. Group differences deserve attention without turning racial or ethnic identity into a personal diagnosis. A similar biomarker relationship deserves attention without being presented as proof of equal accuracy for every test.
For adults concerned about cognitive aging, the long-term value lies in research that supports more carefully grounded assessment. Today’s practical focus remains understanding what a test is being used for and discussing personal memory concerns with a qualified clinician.
Separating a clinical testing question from a daily-habit decision is the practical task here, and FitBrainLab explains the evidence behind that distinction. For adults 60+ uncertain about which everyday habits support cognitive health, its research-led articles clarify findings and open questions without turning laboratory headlines into personal health promises.
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.
Build habits that support memory, focus and a curious, connected life.
Read the Blog
